Synthesis of an RBM39 Degrader That Downregulates CEP192 and Induces Disorganized Spindle Structures

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Xilin Lyu, Xiancheng Wang, Dongze Lin, Yuhan Lu, Chenxu Wang, Ziqin Yan, Zhiyi Wang, Ying Cheng, Jing Cheng, Xuelian Ren, Yi Su, Shijie Zhang, Yi Chen, He Huang, Yujun Zhao
{"title":"Synthesis of an RBM39 Degrader That Downregulates CEP192 and Induces Disorganized Spindle Structures","authors":"Xilin Lyu, Xiancheng Wang, Dongze Lin, Yuhan Lu, Chenxu Wang, Ziqin Yan, Zhiyi Wang, Ying Cheng, Jing Cheng, Xuelian Ren, Yi Su, Shijie Zhang, Yi Chen, He Huang, Yujun Zhao","doi":"10.1021/acs.jmedchem.5c00534","DOIUrl":null,"url":null,"abstract":"RBM39 is an essential component of the spliceosome, playing a critical role in maintaining mRNA integrity. Its depletion significantly exacerbates RNA splicing defects and demonstrates potent anticancer activity. To identify key effectors following RBM39 depletion, we employed a multiomics approach to directly compare two structurally distinct compounds, CB039 and Indisulam. Through proteomic analysis, RNA sequencing, and DepMap dependency assessment, CEP192 emerged as a crucial gene, exhibiting dependency in 96% of the 1,100 analyzed cancer cell lines. In eight cancer cell lines, treatment with both CB039 and Indisulam consistently induced CEP192 exon 42 skipping and reduced CEP192 protein levels. Mechanistically, either CB039 treatment or RNA interference-mediated CEP192 knockdown led to a significant increase in spindle disorganization, as well as chromosome condensation and failed segregation. In conclusion, our characterization of the downstream effects of RBM39 depletion provides novel insights into the therapeutic potential of RBM39 degraders.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"56 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00534","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

RBM39 is an essential component of the spliceosome, playing a critical role in maintaining mRNA integrity. Its depletion significantly exacerbates RNA splicing defects and demonstrates potent anticancer activity. To identify key effectors following RBM39 depletion, we employed a multiomics approach to directly compare two structurally distinct compounds, CB039 and Indisulam. Through proteomic analysis, RNA sequencing, and DepMap dependency assessment, CEP192 emerged as a crucial gene, exhibiting dependency in 96% of the 1,100 analyzed cancer cell lines. In eight cancer cell lines, treatment with both CB039 and Indisulam consistently induced CEP192 exon 42 skipping and reduced CEP192 protein levels. Mechanistically, either CB039 treatment or RNA interference-mediated CEP192 knockdown led to a significant increase in spindle disorganization, as well as chromosome condensation and failed segregation. In conclusion, our characterization of the downstream effects of RBM39 depletion provides novel insights into the therapeutic potential of RBM39 degraders.

Abstract Image

下调CEP192并诱导无序纺锤体结构的RBM39降解物的合成
RBM39是剪接体的重要组成部分,在维持mRNA完整性方面发挥关键作用。它的缺失显著加剧了RNA剪接缺陷,并显示出有效的抗癌活性。为了确定RBM39耗竭后的关键效应物,我们采用多组学方法直接比较了两种结构不同的化合物CB039和吲哚兰。通过蛋白质组学分析、RNA测序和DepMap依赖性评估,CEP192成为了一个关键基因,在1100个分析的癌细胞系中,有96%的癌细胞系都表现出依赖性。在8种癌细胞系中,CB039和茚二唑仑均可诱导CEP192外显子42跳变,并降低CEP192蛋白水平。从机制上讲,CB039处理或RNA干扰介导的CEP192敲低导致纺锤体解体、染色体凝聚和分离失败的显著增加。总之,我们对RBM39缺失的下游效应的描述为RBM39降解物的治疗潜力提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信